ARSUF
Price
$20.03
Change
-$0.82 (-3.93%)
Updated
Oct 29 closing price
Capitalization
1.27B
BIOVF
Price
$29.25
Change
+$2.19 (+8.09%)
Updated
Jun 26 closing price
Capitalization
5.81B
Interact to see
Advertisement

ARSUF vs BIOVF

Header iconARSUF vs BIOVF Comparison
Open Charts ARSUF vs BIOVFBanner chart's image
Fagron SA
Price$20.03
Change-$0.82 (-3.93%)
Volume$425
Capitalization1.27B
Swedish Orphan Biovitrum AB
Price$29.25
Change+$2.19 (+8.09%)
Volume$235
Capitalization5.81B
ARSUF vs BIOVF Comparison Chart in %
Loading...
BIOVF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARSUF vs. BIOVF commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARSUF is a Hold and BIOVF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (ARSUF: $20.03 vs. BIOVF: $29.25)
Brand notoriety: ARSUF and BIOVF are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ARSUF: 100% vs. BIOVF: 18%
Market capitalization -- ARSUF: $1.27B vs. BIOVF: $5.81B
ARSUF [@Pharmaceuticals: Other] is valued at $1.27B. BIOVF’s [@Pharmaceuticals: Other] market capitalization is $5.81B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARSUF’s FA Score shows that 1 FA rating(s) are green whileBIOVF’s FA Score has 0 green FA rating(s).

  • ARSUF’s FA Score: 1 green, 4 red.
  • BIOVF’s FA Score: 0 green, 5 red.
According to our system of comparison, ARSUF is a better buy in the long-term than BIOVF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIOVF’s TA Score shows that 4 TA indicator(s) are bullish.

  • BIOVF’s TA Score: 4 bullish, 4 bearish.

Price Growth

ARSUF (@Pharmaceuticals: Other) experienced а 0.00% price change this week, while BIOVF (@Pharmaceuticals: Other) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.02%. For the same industry, the average monthly price growth was +2.94%, and the average quarterly price growth was +92.60%.

Industries' Descriptions

@Pharmaceuticals: Other (+2.02% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BIOVF($5.81B) has a higher market cap than ARSUF($1.27B). BIOVF has higher P/E ratio than ARSUF: BIOVF (19.92) vs ARSUF (17.83). BIOVF YTD gains are higher at: 5.748 vs. ARSUF (0.000). BIOVF has higher annual earnings (EBITDA): 6.96B vs. ARSUF (136M). BIOVF has more cash in the bank: 790M vs. ARSUF (119M). ARSUF has less debt than BIOVF: ARSUF (385M) vs BIOVF (28.2B). BIOVF has higher revenues than ARSUF: BIOVF (20.1B) vs ARSUF (727M).
ARSUFBIOVFARSUF / BIOVF
Capitalization1.27B5.81B22%
EBITDA136M6.96B2%
Gain YTD0.0005.748-
P/E Ratio17.8319.9289%
Revenue727M20.1B4%
Total Cash119M790M15%
Total Debt385M28.2B1%
FUNDAMENTALS RATINGS
ARSUF vs BIOVF: Fundamental Ratings
ARSUF
BIOVF
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
83
Overvalued
PROFIT vs RISK RATING
1..100
10052
SMR RATING
1..100
6065
PRICE GROWTH RATING
1..100
5858
P/E GROWTH RATING
1..100
5594
SEASONALITY SCORE
1..100
25n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARSUF's Valuation (27) in the null industry is somewhat better than the same rating for BIOVF (83). This means that ARSUF’s stock grew somewhat faster than BIOVF’s over the last 12 months.

BIOVF's Profit vs Risk Rating (52) in the null industry is somewhat better than the same rating for ARSUF (100). This means that BIOVF’s stock grew somewhat faster than ARSUF’s over the last 12 months.

ARSUF's SMR Rating (60) in the null industry is in the same range as BIOVF (65). This means that ARSUF’s stock grew similarly to BIOVF’s over the last 12 months.

ARSUF's Price Growth Rating (58) in the null industry is in the same range as BIOVF (58). This means that ARSUF’s stock grew similarly to BIOVF’s over the last 12 months.

ARSUF's P/E Growth Rating (55) in the null industry is somewhat better than the same rating for BIOVF (94). This means that ARSUF’s stock grew somewhat faster than BIOVF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARSUFBIOVF
RSI
ODDS (%)
N/A
Bullish Trend 4 days ago
43%
Stochastic
ODDS (%)
N/A
Bullish Trend 4 days ago
40%
Momentum
ODDS (%)
N/A
Bearish Trend 4 days ago
62%
MACD
ODDS (%)
N/A
Bearish Trend 4 days ago
56%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
20%
Bullish Trend 4 days ago
50%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
22%
Bearish Trend 4 days ago
43%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
N/A
Bullish Trend 4 days ago
47%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
BIOVF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SAEF26.730.25
+0.96%
Schwab Ariel ESG ETF
USEP37.050.14
+0.38%
Innovator US Equity Ultra Buffer ETF-Sep
CBOJ25.660.01
+0.02%
Calamos Bitcoin Str Alt Prt ETF-Jan
EMLC25.30-0.01
-0.04%
VanEck JPMorgan EMLcl Ccy Bd ETF
BFK9.64-0.01
-0.10%
BlackRock Municipal Income Trust

ARSUF and

Correlation & Price change

A.I.dvisor tells us that ARSUF and GENPF have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ARSUF and GENPF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARSUF
1D Price
Change %
ARSUF100%
N/A
GENPF - ARSUF
23%
Poorly correlated
N/A
AVCNF - ARSUF
11%
Poorly correlated
-2.21%
ALID - ARSUF
8%
Poorly correlated
N/A
BOIRF - ARSUF
1%
Poorly correlated
N/A
BIOVF - ARSUF
1%
Poorly correlated
N/A
More

BIOVF and

Correlation & Price change

A.I.dvisor tells us that BIOVF and SFOSF have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BIOVF and SFOSF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIOVF
1D Price
Change %
BIOVF100%
N/A
SFOSF - BIOVF
21%
Poorly correlated
N/A
BIOYF - BIOVF
7%
Poorly correlated
N/A
BOIRF - BIOVF
1%
Poorly correlated
N/A
ARSUF - BIOVF
1%
Poorly correlated
N/A
BKUH - BIOVF
0%
Poorly correlated
N/A
More